Patsatsi Aikaterini, Kyriakou Aikaterini
2nd Department of Dermatology, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece.
2nd Department of Dermatology, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece.
Clin Dermatol. 2021 Jan-Feb;39(1):52-55. doi: 10.1016/j.clindermatol.2020.12.012. Epub 2020 Dec 15.
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, medical professionals have been overwhelmed by questions beyond the infection itself. In dermatology practice, clinicians have been facing difficulties about the management of chronic immune-mediated skin diseases. Issues arose, such as the grade of immunosuppression or immunomodulation, discontinuation or modification of treatment, and initiation of new treatments. In this comprehensive review, we present the current evidence about the course and management of chronic inflammatory dermatoses during the COVID-19 pandemic, focusing on psoriasis, atopic dermatitis, and hidradenitis suppurativa.
自2019冠状病毒病（COVID-19）大流行开始以来，医学专业人员被感染本身之外的问题压得喘不过气来。在皮肤科实践中，临床医生在慢性免疫介导性皮肤病的管理方面一直面临困难。出现了一些问题，如免疫抑制或免疫调节的程度、治疗的中断或调整以及新治疗方法的启动。在这篇综述中，我们介绍了COVID-19大流行期间慢性炎症性皮肤病的病程和管理的当前证据，重点关注银屑病、特应性皮炎和化脓性汗腺炎。
